PRP Increases Stem Cell Migration by Activating Key Proteins, Study Finds

Researchers are examining how platelet-rich plasma may help adipose-derived stem cells move more effectively to support muscle repair.

Key findings

  • PRP increases migration of adipose-derived stem cells (ADSCs) in vitro, by up to 3x
  • Higher PRP concentrations seemed to correlate with higher migration
  • PRP appeared to upregulate key proteins linked to cell movement (FAK, paxillin, vinculin)
  • PRP alters ADSC cytoskeletal structure and spreading

PRP Likely Boosts Stem Cell Movement for Muscle Repair

Skeletal muscle injuries are a common setback for athletes, often interrupting rigorous training regimens and competition schedules. In recent years, both platelet-rich plasma (PRP) and adipose-derived stem cell (ADSC) therapies have attracted a lot of attention. As you likely know, PRP is rich in growth factors and signaling molecules, while ADSCs have shown the ability to self-renew and become various orthopedic cell types.

In this study, published in JSRMs Regenerative Therapy, researchers set out to investigate whether PRP could enhance the movement (migration) of ADSCs, an important step for tissue repair and regeneration. ADSCs were isolated from the subcutaneous fat of Sprague Dawley rats, then exposed to PRP in the lab to observe the behavior and signaling changes.

The Findings and Key Regenerative Pathways

To assess the effects, the researchers used a series of in vitro assays. In wound healing, migration, and cell spreading tests, ADSCs treated with PRP demonstrated up to 300% better movement and spreading compared to untreated cells.

Further analysis revealed that PRP treatment increased the levels of both total and phosphorylated forms of focal adhesion kinase (FAK) and paxillin, as well as vinculin, proteins that regulate how cells adhere and move, which is critical for the repair process.

Immunofluorescence staining was used to examine the cytoskeleton of the ADSCs, focusing on filamentous actin (F-actin) structures essential for cell shape and movement. PRP treatment led to notable changes in the distribution of F-actin, indicating cytoskeletal rearrangement in these cells.

To confirm the importance of FAK and paxillin, the researchers used siRNA to selectively decrease their levels in the cells. After siRNA knockdown, migration dropped to 120% of control vs. 300% in unmodified PRP-treated cells, suggesting direct dependence on FAK/paxilin for migration.

Implications for Regenerative Therapies

Altogether, the findings suggest that PRP can enhance the migration and spreading of adipose-derived stem cells, supporting the idea that combining PRP and ADSCs could be beneficial in regenerative medicine, particularly for muscle repair.

It’s exciting, but it’s also important to note that this was done in vitro with rat cells and requires further in vivo studies to measure the clinical translation to humans. 

Want to keep up on regenerative medicine? Get the weekly newsletter here.

If you found this post helpful, would you mind sharing it? ⬇️ 

Related:

GwoXi’s FDA filing aims to support cell therapy and exosome developers with a standardized, traceable stem cell source.
The company says its platform may fundamentally change how cartilage loss and degenerative joint disease is treated globally.
Based on their results in Korea/Japan, they received a Phase 3 fast track in the USA, and hope to show true cartilage regeneration. Potentially historic moment for the industry coming.
The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.

The Latest:

A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
The lipid microbubble platform aims to enhance cell therapy manufacturing, adapted from its clinically validated ultrasound imaging tech.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
Long-term follow-up suggests ProTrans may help preserve insulin production, with results varying by dose.
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.
Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the Phase III soon.
The company's autologous cartilage repair product will now be reimbursed under national health insurance, WOMAC scores improved better than hyaluronic acid injections.

Discover more from Regen Report

Subscribe now to keep reading and get access to the full archive.

Continue reading

Stay updated on Regenerative Medicine